However, why are these 34 drugs particularly? Below we have listed the basic information of these drugs, the market situation in China and also the registration progress in China, from which we may understand the reasons why these 34 drugs are selected into the first batch of encouraged generic drugs.

The release of this list is considered as the follow-up of two previous important documents on generic drugs supply issued by China authority in 2018, one of which is the “Opinions on Reforming and Improving the Supply and Protection Policy of Generic Drugs” by the General Office of the State Council, and the other is the “Notice of Printing and Distributing the Work Plan for Accelerating the Implementation of Generic Drugs Supply Guarantee Policy” issued by NHC and other 12 ministries. In these two documents, it is proposed that China will regularly publish lists of encouraged generic drugs: before the end of June 2019, the first list will be released; from year 2020 onwards, such list will be released at the end of each year. And according to the “Notice”, for drugs in these encouraged lists, the priority review and approval pathway shall be applicable in the process of MA application to China NMPA.

So far it’s the 1^st batch of list issued by China NHC, and the publicity time is 5 working days. However, the corresponding favorable policy details for the listed drugs have not been announced yet.